BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18953491)

  • 1. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
    Chamberlain MC; Johnston S
    J Neurooncol; 2009 Feb; 91(3):359-67. PubMed ID: 18953491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC; Wei-Tsao DD; Blumenthal DT; Glantz MJ
    Cancer; 2008 May; 112(9):2038-45. PubMed ID: 18361434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC; Tsao-Wei DD; Groshen S
    Cancer; 2006 Jan; 106(1):172-9. PubMed ID: 16323194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
    Chamberlain MC; Glantz MJ
    J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC; Kim BT
    J Neurooncol; 2017 Jul; 133(3):561-569. PubMed ID: 28500559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
    Chamberlain MC
    Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
    Chamberlain MC; Johnston SK
    Cancer; 2009 Oct; 115(20):4775-82. PubMed ID: 19569246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
    Chamberlain MC
    J Neurooncol; 2015 Apr; 122(2):329-38. PubMed ID: 25563816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Chamberlain MC; Colman H; Kim BT; Raizer J
    J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy with CPT-11 for recurrent meningioma.
    Chamberlain MC; Tsao-Wei DD; Groshen S
    J Neurooncol; 2006 Jul; 78(3):271-6. PubMed ID: 16628476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
    Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
    Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for recurrent ependymoma.
    Green RM; Cloughesy TF; Stupp R; DeAngelis LM; Woyshner EA; Ney DE; Lassman AB
    Neurology; 2009 Nov; 73(20):1677-80. PubMed ID: 19917990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
    Strowd RE; Abuali I; Ye X; Lu Y; Grossman SA
    J Neurooncol; 2016 Mar; 127(1):165-71. PubMed ID: 26729269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.